National Cancer Institute support for targeted alpha-emitter therapy

Hong, Julie A.; Brechbiel, Martin W.; Buchsbaum, J.; Canaria, Christie A.; Coleman, C. Norman; Escorcia, Freddy E.; Espey, Michael Graham; Kunos, Charles; Lin, Frank I.; Narayanan, Deepa; Capala, Jacek

doi:10.1007/s00259-021-05503-z

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the NCI (National Cancer Institute), the IC50 value for a potent compound that can be further developed as an anticancer agent is <20 μg/mL. 15 From this result, the fractions that have the potential to be further developed are the ethyl acetate and n-hexane fractions. Values are presented as mean ± SD; n = 5 replicates; p-value < 0.05 indicates statistically significant differences in comparison to other fractions.…”

Section: Resultsmentioning

confidence: 99%

In vitro Cytotoxic Potential of Sterculia quadrifida Leaf Extract Against Human Breast Cancer Cell Lines

2022

TJNPR

View full text Add to dashboard Cite

The collection locations are S 10° 07' 40"-10°17' 39" and E 123° 31' 35"-123° 41' 00". Kupang City has a low average annual rainfall (1,290 mm/year). The average humidity is 77%, and the average temperature is 27.5°C. The plant was identified at the Laboratory of Herbal Materia Medica Batu, Indonesia. The root, stem, and leaf parts of the plant were authenticated using the Flora of Java book. The remaining plant sample was labeled as Sterculia quadrifida and deposited in the

show abstract

Section: Resultsmentioning

confidence: 99%

In vitro Cytotoxic Potential of Sterculia quadrifida Leaf Extract Against Human Breast Cancer Cell Lines

2022

TJNPR

View full text Add to dashboard Cite

show abstract

“…Support for trainees is important to ensure a supply of experts in the relevant disciplines. Isotope production capabilities must meet anticipated demand and there is a need to enhance the visibility of centers developing new radiopharmaceuticals to promote cross‐institutional partnerships 13 …”

Section: Summary Of the Initial Workhop Of 2021mentioning

confidence: 99%

The United States Department of Energy and National Institutes of Health Collaboration: Medical Care Advances via Discovery in Physical Sciences

et al. 2023

Self Cite

View full text Add to dashboard Cite

Over several months, representatives from the U.S. Department of Energy (DOE) Office of Science and National Institutes of Health (NIH) had a number of meetings that lead to the conclusion that innovations in the Nation's health care could be realized by more directed interactions between NIH and DOE. It became clear that the expertise amassed and instrumentation advances developed at the DOE physical science laboratories to enable cutting-edge research in particle physics could also feed innovation in medical healthcare.To meet their scientific mission, the DOE laboratories created advances in such technologies as particle beam generation, radioisotope production, high-energy particle detection and imaging, superconducting particle accelerators, superconducting magnets, cryogenics, high-speed electronics, artificial intelligence, and big data.

show abstract

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Koleva-Kolarova

Buchanan

Vellekoop

et al. 2022

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background The number of healthcare interventions described as ‘personalised medicine’ (PM) is increasing rapidly. As healthcare systems struggle to decide whether to fund PM innovations, it is unclear what models for financing and reimbursement are appropriate to apply in this context. Objective To review financing and reimbursement models for PM, summarise their key characteristics, and describe whether they can influence the development and uptake of PM. Methods A literature review was conducted in Medline, Embase, Web of Science, and Econlit to identify studies published in English between 2009 and 2021, and reviews published before 2009. Grey literature was identified through Google Scholar, Google and subject-specific webpages. Articles that described financing and reimbursement of PM, and financing of non-PM were included. Data were extracted and synthesised narratively to report on the models, as well as facilitators, incentives, barriers and disincentives that could influence PM development and uptake. Results One hundred and fifty-three papers were included. Research and development of PM was financed through both public and private sources and reimbursed largely through traditional models such as single fees, Diagnosis-Related Groups, and bundled payments. Financial-based reimbursement, including rebates and price-volume agreements, was mainly applied to targeted therapies. Performance-based reimbursement was identified mainly for gene and targeted therapies, and some companion diagnostics. Gene therapy manufacturers offered outcome-based rebates for treatment failure for interventions including Luxturna ® , Kymriah ® , Yescarta ® , Zynteglo ®, Zolgensma ® and Strimvelis ® , and coverage with evidence development for Kymriah ® and Yescarta ® . Targeted testing with OncotypeDX ® was granted value-based reimbursement through initial coverage with evidence development. The main barriers and disincentives to PM financing and reimbursement were the lack of strong links between stakeholders and the lack of demonstrable benefit and value of PM. Conclusions Public-private financing agreements and performance-based reimbursement models could help facilitate the development and uptake of PM interventions with proven clinical benefit. Supplementary Information The online version contains supplementary material available at 10.1007/s40258-021-00714-9.

show abstract

National Cancer Institute support for targeted alpha-emitter therapy

Cited by 4 publications

References 26 publications

In vitro Cytotoxic Potential of Sterculia quadrifida Leaf Extract Against Human Breast Cancer Cell Lines

In vitro Cytotoxic Potential of Sterculia quadrifida Leaf Extract Against Human Breast Cancer Cell Lines

The United States Department of Energy and National Institutes of Health Collaboration: Medical Care Advances via Discovery in Physical Sciences

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Contact Info

Product

Resources

About